Post-marketing Surveillance Protocol Number; CABL001A1401
Phase 4
Recruiting
- Conditions
- Chronic myeloid leukemia resistant or intolerant to pretreatment drugs
- Registration Number
- JPRN-jRCT2031220191
- Lead Sponsor
- Toshiya Sugimoto
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 440
Inclusion Criteria
All patients treated with asciminib
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the safety profile of the safety specifications (myelosuppression, infections, QT interval prolongation, pancreatitis, vascular occlusive events, photosensitivity)
- Secondary Outcome Measures
Name Time Method